logo

Regeneron Pharmaceuticals (REGN)



Trade REGN now with
  Date
  Headline
1/27/2023 8:38:41 AM Regeneron : Dupixent Recommended For EU Approval To Treat Children With Severe Atopic Dermatitis
1/5/2023 8:11:47 AM Sensei Biotherapeutics Enters Supply Deal With Regeneron For Phase 1/2 Trial Of SNS-101 With Libtayo In Solid Tumors
12/23/2022 8:33:28 AM Regeneron : Libtayo Approved In Japan For Advanced Or Recurrent Cervical Cancer
12/21/2022 7:25:18 PM Regeneron : Positive Dupixent Phase 3 Results In Adults &Adolescents With Eosinophilic Esophagitis Published
12/16/2022 7:32:45 AM Regeneron : Dupixent Recommended For EU Approval By CHMP For Treatment Of Eosinophilic Esophagitis
12/15/2022 1:03:14 AM Regeneron Pharma, Sanofi: EC Expands Marketing Authorization For Dupixent In The European Union For Prurigo Nodularis
12/12/2022 10:06:43 AM Regeneron : Linvoseltamab Initial Phase 2 Data Show Meaningful Responses In Heavily Pre-treated Multiple Myeloma
12/11/2022 12:12:30 PM Regeneron Announces Positive Data From Phase 2 Trial Of Odronextamab In Patients With R/R Diffuse Large B-cell Lymphoma
11/30/2022 8:06:22 AM Regeneron Evkeeza SBLA For Children With Ultra-rare Inherited Form Of High Cholesterol Accepted For FDA Priority Review
11/22/2022 7:04:14 AM Regeneron's Libtayo Approved By EC As First Immunotherapy In Second Line Recurrent Or Metastatic Cervical Cancer